Bluebird Bio

Bluebird Bio, based in Cambridge, MA, is dedicated to advancing curative gene therapies aimed at providing patients and their families with improved health outcomes. With a focus on conditions such as beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy, the company has established itself as a leader in the field of gene therapy through its innovative approaches and extensive research.

Known for its proprietary lentiviral vector gene therapies, Bluebird Bio offers one-time treatments designed to deliver functional copies of genes to patients' own cells. Over more than a decade, the company has accumulated the largest and most comprehensive ex-vivo gene therapy data set globally, positioning itself at the forefront of gene therapy advancements while maintaining a commitment to patient-centered care and collaboration.

Generated from the website